H.R. 3503 · 118th Congress (2023–2025)
NIH Clinical Trial Diversity Act of 2023
This bill sets out requirements to increase the diversity of clinical trial participants and requires other activities to foster participation in clinical trials.
As a condition of approval from the National Institutes of Health (NIH) for a clinical trial investigating a drug, device, or behavioral intervention, a sponsor's application must include certain information related to diversity in its trial, such as
- goals for recruiting and retaining trial participants,
- plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements, and
- requirements for researchers and other individuals involved with the trial to complete education and training about diversity in clinical trials.
A sponsor must also annually share demographic data of clinical trial participants with the NIH. The NIH must publish on its website information about the diversity of and other information concerning the clinical trials it funds.
If a sponsor fails to meet its diversity goals or related requirements, the sponsor must develop and implement a strategic plan to increase the diversity of the clinical trial participants.
Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.
The bill also requires studies on barriers to participation in clinical trials. The Government Accountability Office must study actions taken by federal agencies to address such barriers while the NIH must study regulations that govern reimbursements of out-of-pocket expenses of and incentives for clinical trial participants.
Show official title
To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 3503’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Robin L. Kelly (D-IL-2)
- Cosponsors
40 cosponsors
1 original · 39 later
1 R · 39 D
- Rep. Brian K. Fitzpatrick (R-PA-1)· Original · May 18, 2023
- Rep. Anna G. Eshoo (D-CA-16)· Later · May 31, 2023
- Rep. Gwen Moore (D-WI-4)· Later · May 31, 2023
- Del. Eleanor Holmes Norton (D-DC)· Later · May 31, 2023
- Rep. Debbie Wasserman Schultz (D-FL-25)· Later · Jun 12, 2023
- Rep. Nanette Diaz Barragán (D-CA-44)· Later · Jun 21, 2023
- Rep. Alma S. Adams (D-NC-12)· Later · Jul 6, 2023
- Rep. Yvette D. Clarke (D-NY-9)· Later · Jul 6, 2023
- Rep. Dean Phillips (D-MN-3)· Later · Jul 6, 2023
- Rep. Tony Cárdenas (D-CA-29)· Later · Jul 10, 2023
- Rep. Pramila Jayapal (D-WA-7)· Later · Jul 10, 2023
- Rep. Colin Z. Allred (D-TX-32)· Later · Jul 18, 2023
- Rep. William R. Keating (D-MA-9)· Later · Aug 4, 2023
- Rep. Sean Casten (D-IL-6)· Later · Aug 11, 2023
- Rep. Ted Lieu (D-CA-36)· Later · Sep 12, 2023
- Rep. Mark Pocan (D-WI-2)· Later · Sep 12, 2023
- Rep. Lisa Blunt Rochester (D-DE)· Later · Sep 26, 2023
- Rep. James A. Himes (D-CT-4)· Later · Sep 26, 2023
- Rep. Henry C. "Hank" Johnson, Jr. (D-GA-4)· Later · Sep 26, 2023
- Rep. Brittany Pettersen (D-CO-7)· Later · Sep 26, 2023
- Rep. Seth Magaziner (D-RI-2)· Later · Oct 11, 2023
- Rep. Bonnie Watson Coleman (D-NJ-12)· Later · Oct 11, 2023
- Rep. Jill N. Tokuda (D-HI-2)· Later · Oct 19, 2023
- Rep. Yadira Caraveo (D-CO-8)· Later · Oct 26, 2023
- Rep. Andy Kim (D-NJ-3)· Later · Nov 29, 2023
- Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 29, 2024
- Rep. Sheila Jackson Lee (D-TX-18)· Later · Mar 26, 2024
- Rep. Joe Neguse (D-CO-2)· Later · Mar 29, 2024
- Rep. Joseph D. Morelle (D-NY-25)· Later · Apr 23, 2024
- Rep. Becca Balint (D-VT)· Later · May 6, 2024
- Rep. Mark DeSaulnier (D-CA-10)· Later · May 6, 2024
- Rep. Stephen F. Lynch (D-MA-8)· Later · May 6, 2024
- Rep. Grace F. Napolitano (D-CA-31)· Later · May 6, 2024
- Rep. Scott H. Peters (D-CA-50)· Later · May 6, 2024
- Rep. Jason Crow (D-CO-6)· Later · May 21, 2024
- Rep. Jennifer L. McClellan (D-VA-4)· Later · May 21, 2024
- Rep. Paul Tonko (D-NY-20)· Later · May 22, 2024
- Rep. Mary Sattler Peltola (D-AK)· Later · Jun 13, 2024
- Rep. Jerrold Nadler (D-NY-12)· Later · Aug 9, 2024
- Rep. Melanie A. Stansbury (D-NM-1)· Later · Dec 5, 2024
- Policy area
- Health
- Subjects
- Congressional oversight
- Government information and archives
- Government studies and investigations
- Health information and medical records
- Medical research
- Minority health
- National Institutes of Health (NIH)
- Research administration and funding
1 more
- Women's health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · May 18, 2023 – May 19, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
NIH Clinical Trial Diversity Act of 2023
Display title, Short title · Introduced in House
To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.
Official title · Introduced in House